Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has appointed Jerry White as a company advisor. A passionate activist, author and social entrepreneur, White is the recipient of numerous human rights and leadership awards, including sharing the Nobel Peace Prize in 1997. In his new role, White will advise MINDCURE on its mission to revolutionize mental health treatments worldwide through the development and scaling of science-backed psychedelic medicine. White shares in the 1997 Nobel Prize for Peace, which was awarded to the International Campaign to Ban Landmines, an organization that he leads. White is a senior Ashoka Fellow and has worked alongside the late Diana, Princess of Wales, and Her Majesty Queen Noor of Jordan. He was also appointed U.S. Deputy Assistant Secretary of State by President Barack Obama. When he was 20, he lost a leg to a landmine while hiking in northern Israel and consequently co-founded Survivor Corps, an organization created by and for survivors to help victims of war rebuild their lives. He is currently a professor of practice at the University of Virginia, where he teaches on religion, violence and strategy. White noted that his own experience learning to build resilience for trauma recovery, as well as engaging large audiences to power global movements, would help MINDCURE and the psychedelics industry advance revolutionary wellness worldwide. “Never shying away from audacious goals, driving transformational global movements, asking the toughest of questions, and translating them to strategy — this is what Jerry brings and why I am so thrilled to welcome him to the advisory board at MINDCURE,” said MINDCURE president and CEO Kelsey Ramsden in the press release. “It’s an honor to welcome a truly noble and humane impact strategist to our advisory board. I look forward to working with Jerry on our visionary strategy to build mental wealth worldwide.”
To view the full press release, visit https://ibn.fm/5gnYS
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork